Gilead Sciences, Inc. (GILD)’s financial ratios: A comprehensive overview

The closing price of Gilead Sciences, Inc. (NASDAQ: GILD) was $79.52 for the day, down -0.88% from the previous closing price of $80.23. In other words, the price has decreased by -$0.71 from its previous closing price. On the day, 5367815 shares were traded. GILD stock price reached its highest trading level at $80.51 during the session, while it also had its lowest trading level at $79.40.

#1 Small-Cap Uranium Stock for Ultra-Fast Gains in 2024

We've uncovered THE ONE small-cap uranium stock that has unearthed a near-surface, high-grade uranium discovery in the Saudi Arabia of Uranium — Canada's prolific Athabasca Basin. Best of all, this small-cap uranium stock is currently flying just below Wall Street's radar… giving you the early-entry opportunity around US$0.30 per share. But that won't last long. Drills are turning right now with results set to be released to the market very, very soon.

Learn all about it in this brand new FREE online report.
Sponsored

Ratios:

Our analysis of GILD’s different ratios will help us gain a deeper understanding of the company. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 12.43 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 12.62. For the most recent quarter (mrq), Quick Ratio is recorded 1.20 and its Current Ratio is at 1.34. In the meantime, Its Debt-to-Equity ratio is 1.12 whereas as Long-Term Debt/Eq ratio is at 1.04.

Upgrades & Downgrades

In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Deutsche Bank on November 09, 2023, initiated with a Hold rating and assigned the stock a target price of $75.

Insider Transactions:

Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Jan 16 when Dickinson Andrew D sold 5,000 shares for $85.78 per share. The transaction valued at 428,900 led to the insider holds 101,534 shares of the business.

Mercier Johanna sold 8,242 shares of GILD for $702,466 on Jan 09. The Chief Commercial Officer now owns 82,729 shares after completing the transaction at $85.23 per share. On Oct 17, another insider, Dickinson Andrew D, who serves as the Chief Financial Officer of the company, sold 5,000 shares for $80.00 each. As a result, the insider received 400,017 and left with 104,003 shares of the company.

Valuation Measures:

Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, GILD now has a Market Capitalization of 99.12B and an Enterprise Value of 117.24B. As of this moment, Gilead’s Price-to-Earnings (P/E) ratio for their current fiscal year is 17.05, and their Forward P/E ratio for the next fiscal year is 10.98. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 4.14. For the stock, the TTM Price-to-Sale (P/S) ratio is 3.63 while its Price-to-Book (P/B) ratio in mrq is 4.44. Its current Enterprise Value per Revenue stands at 4.28 whereas that against EBITDA is 10.97.

Stock Price History:

Over the past 52 weeks, GILD has reached a high of $87.86, while it has fallen to a 52-week low of $72.87. The 50-Day Moving Average of the stock is 80.06, while the 200-Day Moving Average is calculated to be 78.50.

Shares Statistics:

GILD traded an average of 6.84M shares per day over the past three months and 7.91M shares per day over the past ten days. A total of 1.25B shares are outstanding, with a floating share count of 1.24B. Insiders hold about 0.09% of the company’s shares, while institutions hold 89.56% stake in the company. Shares short for GILD as of Jan 11, 2024 were 17.14M with a Short Ratio of 17.14M, compared to 18.5M on Dec 14, 2023. Therefore, it implies a Short% of Shares Outstanding of 1.38% and a Short% of Float of 1.54%.

Dividends & Splits

With its trailing 12-month dividend rate of 2.98, GILD has a forward annual dividend rate of 3.08. Against a Trailing Annual Dividend Yield of 3.71%, it implies a Forward Annual Dividend Yield of 3.77%. The stock’s 5-year Average Dividend Yield is 3.95. The current Payout Ratio is 80.25% for GILD, which recently paid a dividend on Dec 27, 2023 with an ex-dividend date of Dec 13, 2023. Stock splits for the company last occurred on Jan 27, 2013 when the company split stock in a 2:1 ratio.

Earnings Estimates

The firm’s stock currently is rated by 23 analysts. On average, analysts expect EPS of $1.63 for the current quarter, with a high estimate of $1.88 and a low estimate of $1.46, while EPS last year was $1.67. The consensus estimate for the next quarter is $1.6, with high estimates of $2.03 and low estimates of $1.35.

Analysts are recommending an EPS of between $6.5 and $6.07 for the fiscal current year, implying an average EPS of $6.24. EPS for the following year is $6.64, with 28 analysts recommending between $7.41 and $6.03.

Revenue Estimates

It is expected that $90B in revenue will be generated in the current quarter, according to 22 analysts. It ranges from a high estimate of $6.8B to a low estimate of $6.32B. As of the current estimate, Gilead Sciences, Inc.’s year-ago sales were $7.39B, an estimated decrease of -11.60% from the year-ago figure. For the next quarter, 10 analysts are estimating revenue of $5.95B, a decrease of -6.30% over than the figure of -$11.60% in the same quarter last year. There is a high estimate of $6.2B for the next quarter, whereas the lowest estimate is $5.76B.

A total of 27 analysts have provided revenue estimates for GILD’s current fiscal year. The highest revenue estimate was $25.21B, while the lowest revenue estimate was $24.7B, resulting in an average revenue estimate of $24.94B. In the same quarter a year ago, actual revenue was $27.28B, down -8.60% from the average estimate. Based on 27 analysts’ estimates, the company’s revenue will be $25.44B in the next fiscal year. The high estimate is $26.38B and the low estimate is $24.66B. The average revenue growth estimate for next year is up 2.00% from the average revenue estimate for this year.

Leave a Reply

Your email address will not be published. Required fields are marked *

Most Popular